Location History:
- Belmont, CA (US) (2007)
- Taipei Shien, TW (2010)
Company Filing History:
Years Active: 2007-2010
Title: Innovations of Su-Ying Liu in Anti-Angiogenic Agents
Introduction
Su-Ying Liu is a notable inventor based in Taipei Shien, Taiwan. She has made significant contributions to the field of anti-angiogenic agents, focusing on methods to treat conditions associated with angiogenesis. With a total of 2 patents to her name, her work has the potential to impact cancer treatment and other diseases.
Latest Patents
One of her latest patents is ST104P, which is an anti-angiogenic agent. This invention relates to a method of treating non-tumor conditions or diseases associated with angiogenesis in humans or animals. The method involves administering an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7-disulfonic acid linked by methylene bridges in a pharmaceutically acceptable carrier. Another patent for ST104P investigates its anti-angiogenic functions, demonstrating excellent water solubility and low cytotoxicity to endothelial cells. ST104P has been shown to potently inhibit the secretion of matrix metalloproteinases (MMPs) by endothelial cells. Furthermore, it disrupts the migration and tube formation of endothelial cells. The application of ST104P has been found to abolish neovascularization in the chicken chorioallantoic membrane (CAM) in a dose-dependent manner. Additionally, repeated administration of ST104P into Lewis lung carcinoma resulted in delayed tumor growth and prolonged the life span of tumor-bearing mice. These findings indicate that ST104P holds promise for treating cancer and conditions caused by excessive angiogenesis.
Career Highlights
Su-Ying Liu is associated with Sagittarius Life Science Corporation, where she continues her research and development in the field of anti-angiogenic agents. Her work is characterized by a commitment to advancing medical science and improving treatment options for patients.
Collaborations
One of her notable coworkers is Ming-Hong Tai, who contributes to the collaborative efforts in their research endeavors.
Conclusion
Su-Ying Liu's innovative work in developing anti-angiogenic agents like ST104P showcases her dedication to addressing critical health issues. Her contributions have the potential to significantly impact cancer treatment and improve patient outcomes.